PDS Biotechnology Corp Operating Lease, Right-of-Use Asset, Amortization Expense
PDS Biotechnology Corp (PDSB) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-03-27
- PDS Biotechnology Corp operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $0.00.
- PDS Biotechnology Corp operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp operating lease, right-of-use asset, amortization expense for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- PDS Biotechnology Corp operating lease, right-of-use asset, amortization expense for fiscal 2023 was $160.69K, a 33.33% decline from fiscal 2022.
- PDS Biotechnology Corp operating lease, right-of-use asset, amortization expense for fiscal 2022 was $241.03K, a 0.00% decline from fiscal 2021.
- PDS Biotechnology Corp operating lease, right-of-use asset, amortization expense for fiscal 2021 was $241.03K, a 50.00% increase from fiscal 2020.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-03-27 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $40.17K derived: sum of 4 quarters · filed 2025-03-27 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $40.17K derived: sum of 3 quarters · filed 2025-03-27 | $100.43K derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $40.17K derived: sum of 2 quarters · filed 2025-03-27 | $100.43K derived: sum of 3 quarters · filed 2025-03-27 | $160.69K 10-K · filed 2025-03-27 |
| 2023-09-30 | $40.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $100.43K derived: sum of 2 quarters · filed 2024-11-14 | $160.69K 10-Q · filed 2024-11-14 | $220.94K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $60.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $120.51K 10-Q · filed 2024-08-13 | $180.77K derived: sum of 3 quarters · filed 2024-08-13 | $241.03K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $60.26K 10-Q · filed 2024-05-15 | $120.51K derived: sum of 2 quarters · filed 2024-05-15 | $180.77K derived: sum of 3 quarters · filed 2024-05-15 | $241.03K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $60.26K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $120.52K derived: sum of 2 quarters · filed 2024-03-28 | $180.77K derived: sum of 3 quarters · filed 2024-03-28 | $241.03K 10-K · filed 2024-03-28 |
| 2022-09-30 | $60.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $120.52K derived: sum of 2 quarters · filed 2023-11-14 | $180.77K 10-Q · filed 2023-11-14 | $241.03K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $60.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $120.51K 10-Q · filed 2023-08-14 | $180.77K derived: sum of 3 quarters · filed 2023-08-14 | $241.03K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $60.26K 10-Q · filed 2023-05-15 | $120.51K derived: sum of 2 quarters · filed 2023-05-15 | $180.77K derived: sum of 3 quarters · filed 2023-05-15 | $241.03K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $60.26K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $120.52K derived: sum of 2 quarters · filed 2023-03-28 | $180.77K derived: sum of 3 quarters · filed 2023-03-28 | $241.03K 10-K · filed 2023-03-28 |
| 2021-09-30 | $60.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $120.52K derived: sum of 2 quarters · filed 2022-11-14 | $180.78K 10-Q · filed 2022-11-14 | $234.51K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $60.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $120.51K 10-Q · filed 2022-08-08 | $174.25K derived: sum of 3 quarters · filed 2022-08-08 | $239.40K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $60.26K 10-Q · filed 2022-05-11 | $113.99K derived: sum of 2 quarters · filed 2022-05-11 | $179.14K derived: sum of 3 quarters · filed 2022-05-11 | $220.94K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $53.73K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $118.88K derived: sum of 2 quarters · filed 2022-03-31 | $160.68K derived: sum of 3 quarters · filed 2022-03-31 | $160.68K 10-K · filed 2022-03-31 |
| 2020-09-30 | $65.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $106.95K derived: sum of 2 quarters · filed 2021-11-10 | $106.95K 10-Q · filed 2021-11-10 | $106.95K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $41.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $41.80K 10-Q · filed 2021-08-12 | $41.80K derived: sum of 3 quarters · filed 2021-08-12 | $41.80K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | $0.00 derived: sum of 2 quarters · filed 2021-05-13 | $0.00 derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $0.00 derived: sum of 2 quarters · filed 2021-03-18 | $0.00 10-K · filed 2021-03-18 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $0.00 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |